Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.

Heidi FettkeEdmond M KwanPatricia BukczynskaJason A SteenMaria DocantoNicole NgPhillip ParenteAndrew MantSiavash ForoughiCarmel PezaroChristine HauserTu Nguyen-DumontMelissa C SoutheyArun A Azad

Published in: The Prostate (2021)

These data highlight the importance of identifying multiple markers of AR pathway modulation in mCRPC and represent the first instance of the assessment of plasma NCOA2 status as a prognostic biomarker for standard-of-care therapies. Further assessment is warranted to determine if NCOA2 aberrations are a marker of primary resistance to AR pathway inhibitors.

Keyphrases

healthcare
squamous cell carcinoma
small cell lung cancer
palliative care
electronic health record
gene expression
copy number
pain management
data analysis